It seems quite likely given the rapid acceleration in wages was...

It seems quite likely given the rapid acceleration in wages was at the time where the US sales staff rapidly expanded. That department doesn't need to be there in its entirety since the product is licensed (and therefore marketing and sales costs) will be incurred by LMAT who have plenty of money (and the network of established relationships with centres) to do it.

Where investors should be focussed is the the reduction in staff costs (much larger than marketing spend historically) and see how much of that follows into R&D spend. That will drive the cashflow situation. It's a tough balancing act, because at the same time they have to continue to invest in TAVR as a platform as that's the company's focus. If all the majority of savings are driven into R&D - the company would benefit from a complete rebrand as they will require further capital to drive this initiative at some point, unless they get into a partnership earlier than later.